Learn why hCG is co-prescribed with testosterone replacement therapy to protect testicular function, preserve fertility, and maintain intratesticular testosterone levels.
Learn why hCG is co-prescribed with testosterone replacement therapy to protect testicular function, preserve fertility, and maintain intratesticular testosterone levels.
Testosterone replacement therapy raises your testosterone, but it also turns off the body's own signal to make it. Without that signal, the testes go quiet, shrink over time, and lose the ability to produce sperm. Human chorionic gonadotropin, or hCG, replaces the missing signal and keeps the testes working while TRT does its job.
Your body runs testosterone production through a chain of command called the hypothalamic-pituitary-gonadal (HPG) axis. Think of it as a thermostat loop: the brain detects low testosterone, sends a signal down to the pituitary gland, and the pituitary releases luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH is the direct ignition key for the testes. FSH supports sperm production. When you add testosterone from outside the body, the brain reads "enough testosterone," the thermostat shuts off, and LH and FSH drop toward zero. The testes stop receiving their ignition signal entirely [1].
The cells inside the testes that produce testosterone are called Leydig cells. They only make testosterone when LH tells them to. When exogenous testosterone suppresses LH, Leydig cell activity drops sharply, and intratesticular testosterone (ITT), the concentration of testosterone inside the testes themselves, falls far below what circulating blood levels would suggest [2]. This internal testosterone concentration matters enormously for sperm production. Research into approaches that stimulate Leydig cells directly has confirmed that maintaining ITT is the key variable for preserving spermatogenesis, separate from whatever is happening in the bloodstream [2]. The result of uncorrected ITT suppression is testicular atrophy, a gradual reduction in testicular size that many men on TRT without hCG notice within months, alongside a steep decline in sperm count [3][1].
-
When you inject exogenous testosterone, the pituitary stops sending LH to your testes. hCG steps into that gap. It binds the same receptor on Leydig cells that LH uses, telling those cells to keep making testosterone locally, inside the testis itself [2].
Leydig cells sit in the connective tissue between the sperm-producing tubules. Think of them as the testis's own hormone factory. LH is the signal that keeps the factory running, and hCG carries an almost identical molecular key [4]. When exogenous testosterone shuts down the pituitary's LH output, hCG substitutes for that signal directly at the cell surface. The Leydig cell doesn't distinguish between the two; it sees the receptor occupied and resumes testosterone production [5].
This distinction matters more than most men realize. Serum testosterone, the number on your lab report, reflects what's circulating in your blood. Intratesticular testosterone (ITT) is the concentration inside the testis, and it runs far higher than serum levels [2]. Spermatogenesis, the ongoing production of sperm, depends on maintaining that high local concentration. Exogenous testosterone raises serum levels but suppresses Leydig cell output, which collapses ITT and disrupts sperm production [1].
hCG keeps the Leydig cells active, which keeps ITT high, which keeps the sperm assembly line moving. One important caveat: very high hCG doses can trigger a feedback loop in which intermediate steroids accumulate and begin to dampen the LH receptor's own sensitivity [6]. That's why dosing precision matters, and it's the practical reason most protocols use modest, consistent doses rather than large intermittent ones.
| Signal | Source | Target Cell | Effect |
|---|---|---|---|
| LH (natural) | Pituitary gland | Leydig cells | Stimulates testosterone production |
| hCG (exogenous) | Injection | Leydig cells | Same receptor, same stimulation |
| Exogenous testosterone |
The clinical case for adding hCG to a TRT protocol rests on a consistent finding across multiple studies: exogenous testosterone alone suppresses the pituitary signals that keep your testes working, while hCG substitutes for those signals and keeps the machinery running.
Leydig cell tumors, which disrupt normal testicular hormone signaling, offer a useful comparison point. A prospective case-cohort study published in Human Reproduction found that men with disrupted intratesticular testosterone (ITT, the concentration of testosterone inside the testes themselves, which is far higher than what circulates in blood) had measurably lower testicular volume alongside abnormal FSH and LH levels [7]. That pattern mirrors what happens on TRT without hCG: gonadotropins fall, ITT drops, and testicular volume follows.
When hCG is added to a testosterone protocol, it directly targets the Leydig cells, the testosterone-producing cells that sit in the tissue surrounding the sperm-making tubes, and keeps ITT from collapsing. The result, in practice, is a testes that maintain their size rather than shrinking over months of therapy.
The fertility data is where hCG earns its place most clearly. A 2021 review in Current Pharmaceutical Design reported that combination therapy with hCG and FSH promoted spermatogenesis, the ongoing production of sperm, in approximately 80% of men with gonadotropin deficiency, and achieved pregnancy rates in the range of 50% [4]. Put plainly: most men whose testes had stopped making sperm because of missing hormonal signals were able to restart sperm production with the right gonadotropin support.
| Outcome | hCG alone or combined | Source |
|---|---|---|
| Spermatogenesis restored | ~80% of treated men | [4] |
| Pregnancy achieved | ~50% of treated couples | [4] |
| ITT maintained | Yes, even with full LH suppression from TRT | [3] |
| Testicular volume | Preserved with gonadotropin support | [4] |
These numbers apply to men with secondary hypogonadism, where the testes are capable but under-stimulated. For men considering TRT who
Most men on TRT use hCG at doses between 500 and 1,500 IU two to three times per week, injected subcutaneously into the lower abdomen or thigh. That range keeps the testes stimulated without pushing estradiol high enough to cause problems. The dose is always individualized, but the logic behind the schedule is straightforward.
NOT SURE WHERE TO START?
Take our 2-minute hormone & metabolism quiz to see exactly where you stand. Or skip ahead — a $49 lab panel gives you the numbers, a free hormone screen gives you a plan.
The European Academy of Andrology notes that hCG combined with FSH therapy, used over twelve to twenty-four months, promotes spermatogenesis in roughly 80% of patients with secondary hypogonadism [4]. That finding frames hCG as a real clinical tool, not a precautionary add-on. For men on TRT who want to preserve fertility rather than restore it from scratch, lower doses used more frequently tend to keep intratesticular testosterone (the testosterone produced inside the testes themselves, which is what sperm production depends on) within a useful range without large swings in estradiol.
Common dosing tiers clinicians use:
Men on testosterone cypionate, the most common injectable form, typically inject hCG on the same days as testosterone or on alternating days. Spreading injections across the week smooths out hormone peaks and reduces the mid-cycle estradiol spike that a large hCG bolus can trigger. For a detailed walkthrough of injection technique and subcutaneous sites, the TRT injection guide covers the mechanics step by step.
Knowing the dose is only part of the picture. How your body responds to hCG, particularly what happens to estradiol and testicular volume over the first several months, is where monitoring becomes the deciding factor.
hCG earns its place in a TRT protocol when the axis it mimics, the pituitary signal that tells the testes to produce testosterone and sustain sperm, is being suppressed by exogenous testosterone. Whether that matters to you depends on two things: your fertility goals and where your hypogonadism originates.
The clearest case is a man on TRT who wants to preserve the option of fathering children. Secondary hypogonadism, meaning the problem is a weak signal from the brain rather than broken testicular machinery, responds well to hCG because the Leydig cells are intact and capable of responding [4]. A 2021 review in Current Pharmaceutical Design noted that combination therapy with hCG and FSH "was found to promote testicular growth in almost all patients, spermatogenesis in approximately 80% and pregnancy rates in the range of 50%" in men with hypogonadotropic hypogonadism [4]. That is a meaningful success rate for men who started with no measurable sperm production.
Good candidates include:
Primary hypogonadism is a different story. When the testes themselves are the problem, damaged Leydig cells cannot respond to the hCG signal, so adding it provides minimal benefit and introduces unnecessary estradiol elevation risk. hCG stimulates aromatase in testicular tissue, which converts testosterone to estradiol; elevated estradiol suppresses LH and can cause gynecomastia [4]. Men with hormone-sensitive conditions or those with confirmed azoospermia from testicular failure, rather than from gonadotropin suppression, should discuss carefully whether hCG belongs in their protocol. Understanding how [est
Adding hCG to a TRT protocol requires a tighter monitoring schedule than testosterone alone. The main reason: hCG stimulates testicular aromatase, the enzyme that converts testosterone into estradiol, and that conversion accelerates when both testosterone and hCG are on board simultaneously.
Check the following at baseline and at each follow-up visit:
Estradiol elevation is the most common side effect when hCG is added. hCG stimulates aromatase in testicular tissue, and the result shows up on labs as rising E2 alongside rising testosterone [4]. Mild elevation is expected and not inherently harmful. Problematic elevation, typically accompanied by nipple tenderness or water retention, may warrant a low-dose aromatase inhibitor such as anastrozole, though that decision belongs to your prescribing clinician. For a fuller picture of how estradiol and testosterone interact, estradiol and testosterone in men covers the balance in detail.
Hematocrit deserves equal attention. Managing high hematocrit on TRT explains the clinical steps your physician may take if your numbers trend upward. Reading your hormone lab report can help you follow those numbers between visits.
When labs are tracking well, the next question is practical: how is hCG actually dosed and timed within a weekly protocol?
Before your first hCG dose, the conversation with your clinician should cover three things: your fertility timeline, your current lab values, and your delivery method preferences. Getting those three clear turns a general TRT program into a personalized protocol built around your actual priorities.
Start with a baseline lab panel. The European Academy of Andrology recommends confirming low testosterone on repeated morning fasting measurements before initiating or modifying any testosterone therapy, and flagging a hematocrit above 48–50% as a relative contraindication before proceeding [8]. Semen analysis belongs on that list too if fathering children is a near-term goal, since knowing your baseline sperm concentration gives your clinician a real number to track against. A retrospective study found meaningful improvement in sperm concentration and total motile count in men treated with agents that raise gonadotropin activity, reinforcing why a pre-treatment semen baseline matters [9].
Bring these questions to your appointment:
A physician-supervised protocol answers these before the first injection, not after. If you are ready to start that conversation, book a consultation.
When you take testosterone from outside your body, your brain detects adequate testosterone levels and shuts down the signals that normally tell your testes to produce their own. This suppression causes your testes to shrink and stop making sperm over time. hCG mimics the hormone that normally keeps your testes working, maintaining testosterone production inside the testes themselves, which is crucial for preserving fertility and preventing testicular atrophy.
Yes, hCG can be effective for fertility preservation. Studies show that combination therapy with hCG and FSH promotes sperm production in approximately 80% of men with suppressed gonadotropin signaling and achieves pregnancy rates around 50%. hCG keeps your Leydig cells active, which maintains the testosterone concentration inside your testes where sperm production actually depends on it.
Most men on TRT use hCG between 500 and 1,500 IU two to three times per week, injected subcutaneously. Common approaches include 500 IU three times weekly for mild cases, or 1,000-1,500 IU twice weekly for standard support. Your clinician should individualize the dose based on your fertility goals and how your body responds. The actual dose and timing should be determined by your prescribing physician based on your specific situation.
The primary concern is estradiol elevation. hCG stimulates an enzyme in your testicular tissue that converts testosterone to estradiol, which can lead to nipple tenderness or water retention if it gets too high. You should also monitor hematocrit, since testosterone raises red blood cell production. Your clinician will check total and free testosterone, estradiol, hematocrit, and LH/FSH regularly to catch any problems early.
hCG works best if your testes are capable of responding but receiving weak signals from your brain, called secondary hypogonadism. If your testes themselves are damaged, hCG may provide little benefit. If you don't have fertility concerns and don't mind testicular shrinkage, you might not need it. Men with hormone-sensitive conditions should discuss hCG carefully with their clinician, since it can raise estradiol.
Take our 2-minute hormone & metabolism quiz to see exactly where you stand — or jump straight to labs or a free screen with our team.